[1] |
COZZI E, COLPO A, DE SILVESTRO G. The mechanisms of rejection in solid organ transplantation[J]. Transfus Apher Sci, 2017, 56(4): 498-505. DOI: 10.1016/j.transci.2017.07.005.
|
[2] |
LOUPY A, LEFAUCHEUR C. Antibody-mediated rejection of solid-organ allografts[J]. N Engl J Med, 2018, 379(12): 1150-1160. DOI: 10.1056/NEJMra1802677.
|
[3] |
ZHANG X, LIN G, TAN L, et al. Current progress of tacrolimus dosing in solid organ transplant recipients: pharmacogenetic considerations[J]. Biomed Pharmacother, 2018, 102: 107-114. DOI: 10.1016/j.biopha.2018.03.054.
|
[4] |
SCHUTTE-NUTGEN K, THOLKING G, SUWELACK B, et al. Tacrolimus - pharmacokinetic considerations for clinicians[J]. Curr Drug Metab, 2018, 19(4): 342-350. DOI: 10.2174/1389200219666180101104159.
|
[5] |
OBERBAUER R, BESTARD O, FURIAN L, et al. Optimization of tacrolimus in kidney transplantation: new pharmacokinetic perspectives[J]. Transplant Rev (Orlando), 2020, 34(2): 100531. DOI: 10.1016/j.trre.2020.100531.
|
[6] |
BRUNET M, VAN GELDER T, ÅSBERG A, et al. Therapeutic drug monitoring of tacrolimus-personalized therapy: second consensus report[J]. Ther Drug Monit, 2019, 41(3): 261-307. DOI: 10.1097/FTD.0000000000000640.
|
[7] |
Pharmgkb. Clinical annotation for rs776746 related to tacrolimus- dosage/pk (1A)[EB/OL]. [2018-04-24]. https://www.pharmgkb.org/chemical/PA451578/clinicalAnnotation/981203719.
|
[8] |
陈晨, 张晏洁, 贺小露, 等. 他克莫司个体化用药指南解读[J]. 医学研究生学报, 2017, 30(4): 342-347. DOI: 10.16571/j.cnki.1008-8199.2017.04.002.CHEN C, ZHANG YJ, HE XL, et al. Interpretation of tacrolimus guidelines for individualized medication[J]. J Med Postgrad, 2017, 30(4): 342-347. DOI: 10.16571/j.cnki.1008-8199.2017.04.002.
|
[9] |
TRON C, ALLARD M, PETITCOLLIN A, et al. Tacrolimus diffusion across the peripheral mononuclear blood cell membrane: impact of drug transporters[J]. Fundam Clin Pharmacol, 2019, 33(1): 113-121. DOI: 10.1111/fcp.12412.
|
[10] |
LIU X. Transporter-mediated drug-drug interactions and their significance[J]. Adv Exp Med Biol, 2019, 1141: 241-291. DOI: 10.1007/978-981-13-7647-4_5.
|
[11] |
CHU X, LIAO M, SHEN H, et al. Clinical probes and endogenous biomarkers as substrates for transporter drug-drug interaction evaluation: perspectives from the International Transporter Consortium[J]. Clin Pharmacol Ther, 2018, 104(5): 836-864. DOI: 10.1002/cpt.1216.
|
[12] |
WILLIAMSON B, RILEY RJ. Hepatic transporter drug-drug interactions: an evaluation of approaches and methodologies[J]. Expert Opin Drug Metab Toxicol, 2017, 13(12): 1237-1250. DOI: 10.1080/17425255.2017.1404028.
|
[13] |
NIGAM SK. What do drug transporters really do?[J]. Nat Rev Drug Discov, 2015, 14(1): 29-44. DOI: 10.1038/nrd4461.
|
[14] |
LEE W, HA JM, SUGIYAMA Y. Post-translational regulation of the major drug transporters in the families of organic anion transporters and organic anion-transporting polypeptides[J]. J Biol Chem, 2020, 295(50): 17349-17364. DOI: 10.1074/jbc.REV120.009132.
|
[15] |
DARNEY K, TURCO L, BURATTI FM, et al. Human variability in influx and efflux transporters in relation to uncertainty factors for chemical risk assessment[J]. Food Chem Toxicol, 2020, 140: 111305. DOI: 10.1016/j.fct.2020.111305.
|
[16] |
YU M, LIU M, ZHANG W, et al. Pharmacokinetics, pharmacodynamics and pharmacogenetics of tacrolimus in kidney transplantation[J]. Curr Drug Metab, 2018, 19(6): 513-522. DOI: 10.2174/1389200219666180129151948.
|
[17] |
WANG R, SUN X, DENG YS, et al. Effects of MDR1 1236C > T-2677G > T-3435C > T polymorphisms on the intracellular accumulation of tacrolimus, cyclosporine A, sirolimus and everolimus[J]. Xenobiotica, 2019, 49(11): 1373-1378. DOI: 10.1080/00498254.2018.1563732.
|
[18] |
MA G, HUANG X, BI Y, et al. Association study between ABCB1, ABCB6 and ABCG1 polymorphisms and major depressive disorder in the Chinese Han population[J]. Psychiatry Res, 2018, 270: 1170-1171. DOI: 10.1016/j.psychres.2018.05.045.
|
[19] |
GENVIGIR FD, SALGADO PC, FELIPE CR, et al. Influence of the CYP3A4/5 genetic score and ABCB1 polymorphisms on tacrolimus exposure and renal function in Brazilian kidney transplant patients[J]. Pharmacogenet Genomics, 2016, 26(10): 462-472. DOI: 10.1097/FPC.0000000000000237.
|
[20] |
PRASAD N, JAISWAL A, BEHERA MR, et al. Melding pharmacogenomic effect of MDR1 and CYP3A5 gene polymorphism on tacrolimus dosing in renal transplant recipients in Northern India[J]. Kidney Int Rep, 2019, 5(1): 28-38. DOI: 10.1016/j.ekir.2019.09.013.
|
[21] |
胡楠, 汤雨帆, 钱卿, 等. CYP3A5和ABCB1基因多态性对肾移植患者术后初期他克莫司剂量、浓度及肾功能的影响[J]. 中南药学, 2019, 17(4): 489-494. DOI: 10.7539/j.issn.1672-2981.2019.04.002.HU N, TANG YF, QIAN Q, et al. Effect of CYP3A5 and ABCB1 polymorphism on dosage and concentration of tacrolimus and renal function in renal transplant recipients at early postoperative period[J]. Central South Pharm, 2019, 17(4): 489-494. DOI: 10.7539/j.issn.1672-2981.2019.04.002.
|
[22] |
RIEGERSPERGER M, PLISCHKE M, STEINHAUSER C, et al. The effect of ABCB1 polymorphisms on serial tacrolimus concentrations in stable Austrian long-term kidney transplant recipients[J]. Clin Lab, 2016, 62(10): 1965-1972. DOI: 10.7754/Clin.Lab.2016.160221.
|
[23] |
SU L, YIN L, YANG J, et al. Correlation between gene polymorphism and blood concentration of calcineurin inhibitors in renal transplant recipients: an overview of systematic reviews[J]. Medicine (Baltimore), 2019, 98(26): e16113. DOI: 10.1097/MD.0000000000016113.
|
[24] |
刘璐, 宋沧桑, 张阳, 等. MDR1 C3435T基因多态性与肾移植患者他克莫司血药浓度关系的Meta分析[J]. 中国医院药学杂志, 2018, 38(23): 2440-2446. DOI: 10.13286/j.cnki.chinhosppharmacyj.2018.23.12.LIU L, SONG CS, ZHANG Y, et al. A Meta-analysis of correlation between MDR1 C3435T genotypes and blood concentration of tacrolimus in renal transplant recipients[J]. Chin J Hosp Pharm, 2018, 38(23): 2440-2446. DOI: 10.13286/j.cnki.chinhosppharmacyj.2018.23.12.
|
[25] |
PENG W, LIN Y, ZHANG H, et al. Effect of ABCB1 3435C > T genetic polymorphism on pharmacokinetic variables of tacrolimus in adult renal transplant recipients: a systematic review and Meta-analysis[J]. Clin Ther, 2020, 42(10): 2049-2065. DOI: 10.1016/j.clinthera.2020.07.016.
|
[26] |
NAUSHAD SM, PAVANI A, RUPASREE Y, et al. Recipient ABCB1, donor and recipient CYP3A5 genotypes influence tacrolimus pharmacokinetics in liver transplant cases[J]. Pharmacol Rep, 2019, 71(3): 385-392. DOI: 10.1016/j.pharep.2019.01.006.
|
[27] |
CAPRON A, MOURAD M, DE MEYER M, et al. CYP3A5 and ABCB1 polymorphisms influence tacrolimus concentrations in peripheral blood mononuclear cells after renal transplantation[J]. Pharmacogenomics, 2010, 11(5): 703-714. DOI: 10.2217/pgs.10.43.
|
[28] |
HAN SS, YANG SH, KIM MC, et al. Monitoring the intracellular tacrolimus concentration in kidney transplant recipients with stable graft function[J]. PLoS One, 2016, 11(4): e0153491. DOI: 10.1371/journal.pone.0153491.
|
[29] |
NOLL BD, COLLER JK, SOMOGYI AA, et al. Validation of an LC-MS/MS method to measure tacrolimus in rat kidney and liver tissue and its application to human kidney biopsies[J]. Ther Drug Monit, 2013, 35(5): 617-623. DOI: 10.1097/FTD.0b013e31828e8162.
|
[30] |
OGASAWARA K, CHITNIS SD, GOHH RY, et al. Multidrug resistance-associated protein 2 (MRP2/ABCC2) haplotypes significantly affect the pharmacokinetics of tacrolimus in kidney transplant recipients[J]. Clin Pharmacokinet, 2013, 52(9): 751-762. DOI: 10.1007/s40262-013-0069-2.
|
[31] |
GENVIGIR FDV, NISHIKAWA AM, FELIPE CR, et al. Influence of ABCC2, CYP2C8, and CYP2J2 polymorphisms on tacrolimus and mycophenolate sodium-based treatment in Brazilian kidney transplant recipients[J]. Pharmacotherapy, 2017, 37(5): 535-545. DOI: 10.1002/phar.1928.
|
[32] |
PULK RA, SCHLADT DS, OETTING WS, et al. Multigene predictors of tacrolimus exposure in kidney transplant recipients[J]. Pharmacogenomics, 2015, 16(8): 841-854. DOI: 10.2217/pgs.15.42.
|
[33] |
GENVIGIR FDV, CAMPOS-SALAZAR AB, FELIPE CR, et al. CYP3A5*3 and CYP2C8*3 variants influence exposure and clinical outcomes of tacrolimus-based therapy[J]. Pharmacogenomics, 2020, 21(1): 7-21. DOI: 10.2217/pgs-2019-0120.
|
[34] |
LI TT, AN JX, XU JY, et al. Overview of organic anion transporters and organic anion transporter polypeptides and their roles in the liver[J]. World J Clin Cases, 2019, 7(23): 3915-3933. DOI: 10.12998/wjcc.v7.i23.3915.
|
[35] |
OSWALD S. Organic anion transporting polypeptide (OATP) transporter expression, localization and function in the human intestine[J]. Pharmacol Ther, 2019, 195: 39-53. DOI: 10.1016/j.pharmthera.2018.10.007.
|
[36] |
HSUEH CH, YOSHIDA K, ZHAO P, et al. Identification and quantitative assessment of uremic solutes as inhibitors of renal organic anion transporters, OAT1 and OAT3[J]. Mol Pharm, 2016, 13(9): 3130-3140. DOI: 10.1021/acs.molpharmaceut.6b00332.
|
[37] |
PALLIO G, IRRERA N, BITTO A, et al. Failure of achieving tacrolimus target blood concentration might be avoided by a wide genotyping of transplanted patients: evidence from a retrospective study[J]. J Pers Med, 2020, 10(2): 47. DOI: 10.3390/jpm10020047.
|
[38] |
刘澍, 陈荣新, 李军, 等. SLCO1B1基因多态性与肾移植患者他克莫司浓度相关性的研究[J]. 药学学报, 2016, 51(8): 1240-1244. DOI: 10.16438/j.0513-4870.2016-0027.LIU P, CHEN RX, LI J, et al. Associations of SLCO1B1 polymorphisms with tacrolimus concentrations in Chinese renal transplant recipients[J]. Acta Pharm Sin, 2016, 51(8): 1240-1244. DOI: 10.16438/j.0513-4870.2016-0027.
|
[39] |
WU Y, FANG F, WANG Z, et al. The influence of recipient SLCO1B1 rs2291075 polymorphism on tacrolimus dose-corrected trough concentration in the early period after liver transplantation[J]. Eur J Clin Pharmacol, 2021, 77(6): 859-867. DOI: 10.1007/s00228-020-03058-w.
|
[40] |
WANG J, HUANG L, GAO P, et al. Diltiazem on tacrolimus exposure and dose sparing in Chinese pediatric primary nephrotic syndrome: impact of CYP3A4, CYP3A5, ABCB1, and SLCO1B3 polymorphisms[J]. Eur J Clin Pharmacol, 2021, 77(1): 71-77. DOI: 10.1007/s00228-020-02977-y.
|
[41] |
ALAM K, CROWE A, WANG X, et al. Regulation of organic anion transporting polypeptides (OATP) 1B1- and OATP1B3-mediated transport: an updated review in the context of OATP-mediated drug-drug interactions[J]. Int J Mol Sci, 2018, 19(3): 855. DOI: 10.3390/ijms19030855.
|
[42] |
BOIVIN AA, CARDINAL H, BARAMA A, et al. Influence of SLCO1B3 genetic variations on tacrolimus pharmacokinetics in renal transplant recipients[J]. Drug Metab Pharmacokinet, 2013, 28(3): 274-277. DOI: 10.2133/dmpk.dmpk-12-sh-093.
|
[43] |
王翔, 余爱荣, 辛华雯. 相关基因多态性与肾移植术后他克莫司疗效的关系研究进展[J]. 中国药师, 2020, 23(5): 938-941. DOI: 10.3969/j.issn.1008-049X.2020.05.037.WANG X, YU AR, XIN HW. Advances in the relationship between related gene polymorphisms and efficacy of tacrolimus after renal transplantation[J]. Chin Pharm, 2020, 23(5): 938-941. DOI: 10.3969/j.issn.1008-049X.2020.05.037.
|